Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03336268 · ClinicalTrials.gov registry record · NA
Project POINT: Effectiveness and Scalability of an Overdose Survivor Intervention
A NA study of Substance Use Disorders and Overdose, sponsored by Indiana University.
- Completed
- Registry status
- NA
- Development phase
- 249
- Enrollment target
- 2
- Study locations
NCT03336268 is a NA study of Substance Use Disorders and Overdose that has completed, run by Indiana University. The registered enrollment target is 249 participants, below the 497-participant average among 93 other Substance Use Disorders trials with a reported enrollment target (50% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT03336268, a NA study of Substance Use Disorders and Overdose, has completed, sponsored by Indiana University.
- COMPLETED
- Registry status
- NA
- Development phase
- 249 participants
- Enrollment target
- 2
- Study locations
Study Summary
The investigators seek to assess the effectiveness of Project POINT (Planned Outreach, Intervention, Naloxone, and Treatment). As originated in Indianapolis, Project POINT is a collaboration between Indianapolis Emergency Medical Services (EMS), the Eskenazi Emergency Department, Midtown Mental Health, and researchers at Indiana University. POINT is a quality improvement initiative that connects trained outreach workers with emergency department (ED) patients who experienced a non-fatal overdose. A member of the POINT team (a recovery coach or care coordinator with specialized training) meets patients after they have experienced an opioid overdose and, following a model of patient-centered care, offers them a range of evidence-based services including a brief assessment of high-risk behaviors, Hepatitis C and HIV testing, harm reduction counseling informed by motivational interviewing, and treatment referrals with follow-up to either a medication for opioid use disorder (MOUD) provider, detoxification services, or an inpatient treatment setting The primary goal of this project is the establishment of POINT as an effective and scalable intervention for engaging patients in MAT. This study employs a Hybrid Type 1 effectiveness implementation design to take full advantage of current POINT expansion efforts currently happening in Indiana. The goal of this study is to replicate POINT in new hospitals and test its feasibility through (a) assessment of the chosen implementation strategy and (b) the testing of research protocols and secondary data collection procedures.
Conditions Studied
Interventions
- BEHAVIORAL POINT
Study Locations (2)
Indiana
- Indiana University Health Methodist Hospital - Indianapolis
- Indiana University Health Ball Memorial Hospital - Muncie
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 249 participants |
| Start Date | 2018-02-12 |
| Est. Completion | 2021-12-09 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03336268
The ClinicalTrials.gov registry entry for NCT03336268 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 249 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 497-participant average among 93 other Substance Use Disorders trials with a reported enrollment target (50% lower). The listed sponsor is Indiana University, which has 890 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Substance Use Disorders appearing as the primary indexed condition, and to 1 intervention - of which POINT is the first listed.
NCT03336268 reports 2 study locations spanning 1 distinct geographic area - top geographies include Indiana.
Frequently Asked Questions
What is clinical trial NCT03336268 about?
NCT03336268 is a clinical study titled "Project POINT: Effectiveness and Scalability of an Overdose Survivor Intervention". The investigators seek to assess the effectiveness of Project POINT (Planned Outreach, Intervention, Naloxone, and Treatment). As originated in Indianapolis, Project POINT is a collaboration between Indianapolis Emergency Medical Services (EMS), the Eskenazi Emergency Department, Midtown Mental Heal...
What is the current status of trial NCT03336268?
This trial is currently completed. It is a NA study. The enrollment target is 249 participants. The study started on 2018-02-12. Estimated completion is 2021-12-09.
What conditions does trial NCT03336268 study?
This clinical trial studies the following conditions: Substance Use Disorders, Overdose.
What interventions are being tested in trial NCT03336268?
The interventions under investigation include: POINT (BEHAVIORAL).
Who is sponsoring clinical trial NCT03336268?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03336268 being conducted?
This trial has 2 study locations across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Substance Use Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Supporting Treatment Access and Recovery Through Linkage and Support
RECRUITING · NA
-
Development OF A Novel Peer Recovery Supporter Training Platform
RECRUITING · NA
-
Project I Test: Implementing HIV Testing in Opioid Treatment Programs
RECRUITING · NA
-
Testing Strategies to Improve Substance Misuse Prevention Research Use in State Policy Contexts
RECRUITING · NA
-
Families Left Behind
RECRUITING · NA
-
Trauma Screening/Referral and Interpersonal Violence Prevention for Women with Substance Use Disorders
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.